Vimarsana
Biggest News Aggregation in the World

Page 13 - Enterprise Tech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Enterprise Tech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Enterprise Tech Today - Breaking & Trending Today

How 4 Tech Workers Increased Their Salaries by Switching Companies - Vimarsana News

How 4 Tech Workers Increased Their Salaries by Switching Companies

With companies holding bigger budgets for new hires than raises, employees are finding that switching companies is the best way to score better pay.

Data Privacy and Security Leader Privacera Poised for Strong Growth in 2022 - Vimarsana News

Data Privacy and Security Leader Privacera Poised for Strong Growth in 2022

/PRNewswire/ -- Privacera, the unified data access governance leader founded by the creators of Apache Rangerâ„¢, is accelerating growth in 2022 as the data...

CIOs increasingly tap contract IT as talent gap filler - Vimarsana News

CIOs increasingly tap contract IT as talent gap filler

With the percentage of tech workers opting for independent work rising, CIOs are recalculating staffing mixes to lean more heavily on freelance and contract workers for hard-to-hire, high-demand skills.

Source: cio.com
I Was a Teacher for 4 Years. Here's How I Landed a Job at Zoom. - Vimarsana News

I Was a Teacher for 4 Years. Here's How I Landed a Job at Zoom.

Here is how I went from working 60-plus-hour weeks and making $77,000 as a teacher to earning $177,000 in a developer-advocate role at Zoom.

ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets - Vimarsana News

ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets

/PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced...